Introduction
============

Chronic bladder pain (CBP) is a condition characterized by supra-pubic pain or discomfort in the pelvic area related to bladder filling, of at least 6 months of duration ([@r1]). It is often accompanied by wide range of lower urinary tract symptoms, such as frequency, nocturia, and urgency. Patients may refer pain or pressure in the pelvic area and in other areas of the body, including the back and the neck ([@r2]). Some patients present typical cystoscopic findings including bladder glomerulations during hydrodistention and ulcerative areas of the bladder mucosa, known as Hunner's lesion ([@r1]). Bladder biopsy may confirm the diagnosis and exclude confusable diseases ([@r1]). Typical pathological findings include bladder inflammation, mast cell accumulation in the bladder wall and urothelial thinning or disruption ([@r1]).

The aetiology of CBP is unknown. Taking in consideration the morphological changes in the urothelium, such as urothelial thinning, decreased urothelial cell cohesion and loss of the protective glycosaminoglycan layer led to the common belief that CBP is linked to an increase permeability of the urothelium. As a consequence, the diffusion of urine constituents into the bladder wall may induce an intense inflammatory infiltrate, mast cells accumulation and activation of nociceptive fibres ([@r3]). However the causes impairing the ability of the urothelium to maintain a barrier and undergo repair following injury are not clear. The release of an anti-proliferative compound slowing urothelial growth, autoimmune disorders, chronic infection by unknown bacteria, bladder ischemia, changes in nitric oxide metabolism or unknown toxin agents, all have been forward as possible mechanism to the urothelial changes ([@r3]). The leaky urothelium, whatever the cause, it is expected to self-perpetuate bladder inflammation and nociceptive fibres activation ([@r3]).

CBP is frequently associated with other painful syndromes, such as irritable bowel syndrome (IBS), chronic fatigue and fibromyalgia ([@r4]). The reason for such association is unclear, although it might suggest a common systemic background. Here, we will review the evidence supporting the involvement of sympathetic in the etiology of CBP.

Evidence of the sympathetic nervous system dysfunction in patients with CBP
===========================================================================

In a recent work, Charrua and co-workers have analysed the activity of sympathetic nervous system by performing the TILT test in ten female patients with CBP ([@r5]). Ten aged match healthy woman were used as controls. The TILT test analysis the increase in sympathetic nervous system activity generated by the change in body position, measuring the variation of the standard deviation of the P wave interval (∆SDPP, a parameter that inversely correlates with sympathetic activity), the root-mean-square difference among successive normal R-R intervals in heart period series (rMSSD, a parameter that measures the parasympathetic activity) and the average of all baroreflex sequences registered as the test progresses (BRS, a parameter that measures the parasympathetic activity) ([@r5]). Patients with CBP presented a ∆SDPP value of 24.2±18 ms, which was lower than the 57.2±23.0 ms presented by controls, showing an overactivity of sympathetic nervous system ([*Figure 1*](#f1){ref-type="fig"}) ([@r5]). The values of rMSSD, 5.6±8.4 ms, and of BRS, 7.7±8.2 ms/mmHg, presented by CBP patients did not differ from values presented by controls (6.3±2.8 ms and 7.1±3.8 ms/mmHg, respectively) ([@r5]).
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Similarly, Lutgendorf and co-workers examined 14 patients with CBP and 14 healthy individuals and observed that the former had higher resting heart rate and elevated resting diastolic blood pressure, suggesting that these patients harbour an autonomic dysregulation ([@r6]). Also, Williams and co-workers analysed changes in heart rate variability in 26 subjects with CBP and 32 healthy subjects and found that CBP patients had lower vagal activity and a shift toward sympathetic nervous system dominance ([@r7]).

The levels of noradrenaline were analysed by high-performance liquid chromatography (HPLC), in the blood and urine 24 h collected from 18 patients with CBP and ten aged matched controls ([@r5]). Also, plasmatic noradrenaline levels were also analysed after performing the TILT test in CBP patients. It was observed that in supine position, the levels of plasma noradrenaline were higher in CBP patients than healthy subjects ([@r5]). However, no changes in plasma noradrenaline were observed between patients with CBP and healthy subjects in the upright position ([@r5]). Concerning the 24 h urine, CBP patients presented higher levels of noradrenaline than healthy subjects ([@r5]). Altogether, these findings corroborate the overactivity of sympathetic nervous system of CBP patients.

Pinto and co-workers studied if there was a correlation between CBP and the observed increase in noradrenaline levels ([@r8]). For that, they assessed visual analogue scale for pain and analysed urinary noradrenaline levels before and 1 month after intra-trigonal injection of 100 U onabotulinum type A in 16 patients with CBP ([@r8]). These authors have observed a positive correlation between the improvement of visual analogue scale for pain and the decrease in the 24 h urinary norepinephrine excretion, upon onabotulinum type A treatment ([*Figure 2*](#f2){ref-type="fig"}) ([@r8]).
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The above mentioned data is in agreement with other studies that have suggested a relation between CBP and the sympathetic nervous system. Stein and co-workers quantified by ELISA the levels of noradrenaline in the urine of 111 CBP patients and of 92 healthy volunteers ([@r9]). CBP patients had a higher urinary noradrenaline level than healthy volunteers. Urinary noradrenaline levels were investigated in patients presenting the two classical phenotypes of bladder pain syndrome/interstitial cystitis: those with Hunner's lesion and those without lesions ([@r9]). Noradrenaline levels were similar between CBP patients that present and do not present ulcers ([@r9]).

There are also several lines of evidence showing changes in sympathetic innervation in the bladder of CBP patients. Using immunohistochemical stains for the nonselective neuronal marker, protein gene product (PGP) 9.5, Christmas and co-workers observed that the sub-urothelium and the muscular layer of CBP patients presented more nerve fibres than the bladder of healthy subjects ([@r10]). Later on, Hohenfellner and co-workers using bladder tissue from ten patients with CBP, performed immunohistochemical staining against vasoactive intestinal polypeptide (a marker of vasodilator cholinergic nerves) and neuropeptide Y (a marker of vasoconstrictor adrenergic neurons), and verified that CBP patients presented an increase in the number of nerves positive for these targets, showing the existence of sympathetic sprouting ([@r11]). Peeker and co-workers have also observed an increase in the density and number of nerve fibers immunoreactive for tyrosine hydroxylase (an enzyme essential for neuronal catecholamine synthesis and therefore, a marker of adrenergic activity) in the bladders of CBP patients ([@r12]). Hence, CBP has been associated with increased urinary bladder sympathetic innervation.

In normal human bladder, noradrenaline-containing autonomic nerve fibers are found near smooth muscle cells of the vesico-urethra junction ([@r13],[@r14]). It is not known if, during CBP, the sprouting of sympathetic fibres carries them to other bladder regions. In fact, in an animal model of CBP, Charrua and co-workers have observed the sprouting of sympathetic fibres to other bladder regions were sympathetic fibres were scarcely found ([@r5]).

Lundeberg and co-workers have observed more nerve fibres within the sub-urothelium and detrusor muscle in CBP patients with ulcers than in CBP patients who did not present these bladder changes ([@r15]). However, Peeker and co-workers did not observe any differences in the expression of sympathetic fibres among these two populations of CBP patients ([@r12]).

These data suggest that there is an increase in sympathetic nerve fibres expression where activity in the urinary bladder of patients with CBP. However, these studies have not examined whether this sympathetic overactivity triggers or exacerbates CBP.

The sympathetic nervous system and mast cell activation
=======================================================

CBP is often accompanied by bladder inflammation. Different authors have evaluated the migration and activation of mast cell in the bladder wall of patients with CBP and observed an increase in these cells number and activity ([@r16]-[@r24]). When activated, mast cells release molecules that activate/sensitize bladder primary afferents in its close vicinity, promoting the release of neuropeptides that will have a paracrine action further stimulating the mast cells, an event thought to aggravate pain in CBP patients ([@r15],[@r25]-[@r33]). Contrary to the observed role of mast cell---sensory fibres cross-talk in CBP, the cross-talk between mast cells and sympathetic nerve fibres is poorly studied. Hohenfellner and co-workers verified a sprouting of sympathetic fibres in the urinary bladder of patients with CBP ([@r11]). Keith and co-workers showed that the sprouted sympathetic fibres were located near serotonin-immunoreactive mast cells ([@r33]). Also, using an animal model of CBP, Charrua and co-workers observed that chronic adrenergic stimulation lead to an increase in the number of mast cells in the bladder mucosa ([@r5]). Altogether, these data suggest that sympathetic nervous system overactivity promotes mastocytosis, and consequently, augments and likely sustains pain.

Animal models of CBP: sympathetic nervous system implications
=============================================================

Most recently, Charrua and co-workers have developed a model of chronic adrenergic stimulation that mimic most of the signs and symptoms observed in patients with CBP ([@r5]). In this model, female rats subcutaneously received 2.5 mg phenylephrine (PHE)/kg, for 14 days ([@r5]). Visceral pain behaviour, changes in bladder motility and morphology were analysed in rats receiving chronic adrenergic stimulation and in saline treated controls ([@r5]). It was observed that rats receiving chronic adrenergic stimulation had higher pain scores than controls ([@r5]). At day 14, treated animals responded to 9±2 g filaments and non-treated animals responded to 54±13 g, showing a decrease in mechanical pain threshold ([@r5]). Curiously, chronic adrenergic stimulation-induced pain was blocked by depleting nociceptive fibres with a systemic capsaicin (CAP) pre-treatment ([@r5]).

BPS patients tend to empty their bladder at lower volumes than healthy individuals, due to pain associated with bladder filling. Using chronic adrenergic stimulation, Charrua and co-workers also observed that treated animals had increase bladder frequency (8.2±3.6 spots/hour and reflex activity (1.47±0.24 contractions/minute) than control (2.8±1.1 spots/hour and 0.43±0.11 contractions/minute, respectively) ([@r5]). As observed in patients with CBP, animals submitted to chronic adrenergic stimulation presented patchy impaired urothelium, with reduced thickness due to loss of umbrella cells, as observed by lack of cytokeratin 20 staining, and the presence of the pro-apoptotic markers caspase and bax ([@r5]). Also, the urothelial barrier function from animals submitted to chronic adrenergic stimulation is also compromised has it stained for trypan blue ([@r5]). These observations were absent in control animals ([@r5]). Therefore, these data indicates a possible adrenergic contribution for the development of CBP and associated symptoms.

Nevertheless, there are other animal models to study CBP, although all of them presenting important limitation ([@r34]). The most widely used is the intravesical application chemical irritants, such as cyclophosphamide-induced cystitis ([@r35]), lipopolysaccharide-induced cystitis ([@r36]), bladder irritation by intravesical instillation of acetone ([@r37]), turpentine ([@r38]) or acetic acid ([@r39]), or feline interstitial cystitis (FIC) model. Recently, animal models of stress, such as water avoidance stress model, have also been used to study CBP ([@r5],[@r40],[@r41]).

Taking in consideration that during joint inflammation, there is an increase in the density of sympathetic nerve fibres ([@r42]), Charrua and co-workers have investigated whether the same was observed in the rat inflamed bladder ([@r5]). Hence, using a rat model of cystitis induced by intravesical instillation of lipopolysaccharide, these authors studied the vesicle monoamine transporters two expression, a membrane protein that transports monoamines, in the bladder wall and measured urinary noradrenaline ([@r5]). An increase in sympathetic nerve fibres density in the body and dome of muscular and suburothelial layers of inflamed bladders compared to controls was observed ([@r5]). Also, these authors found a great increase in urinary levels of noradrenaline in animals with cystitis, compared to the control ([@r5]), suggesting a possible paracrine effect of noradrenaline in nearby cellular population.

Cats have been shown to exhibit CBP syndrome known as FIC ([@r43]). FIC has similarities with human CBP syndrome, such as pain, decrease in urinary glycosaminoglycan and urothelium structure and function impairment ([@r43]-[@r47]). Reche Júnior and Buffington analysed tyrosine hydroxylase expression in locus coeruleus from six FIC cats, in the quiescent period, and six healthy cats ([@r48]). These authors observed that FIC cats expressed more tyrosine hydroxylase than healthy cats, which suggests an alteration in the sympathetic outflow ([@r48]). Later on, Buffington and Pacak analysed plasma norepinephrine levels using blood samples from eight cats with FIC and eight healthy cats, and concluded that this catecholamine levels were higher in the former group ([@r49]).

The role of stress in CBP is becoming more evident. Lee and co-workers have demonstrated that rats submitted to chronic water avoidance stress resulted in a bladder hyperalgesia ([@r41]). After 10 days of exposing rats in a pedestal placed in the centre of a container filled with water, the animals had higher frequency of responses to lower strength filaments than sham animals ([@r41]), they have showed that these animals presented referred bladder hyperalgesia. Furthermore, these authors also demonstrated that only chronic stress, but not acute stress, could induce such change in pain behaviour ([@r41]), suggesting that the bladder nociceptive pathways activated by chronic stress stimulus differ from acute stress stimulus. Also, these authors have observed changes in colon activity after chronic stress stimuli, showing a possible cross-talk between visceral organs due to their cross-innervation ([@r41]). In fact, previous works have shown the existence of a colon-bladder cross-talk due to activation of colon nociceptive fibres ([@r50]-[@r55]). These data are in accordance with the observation that stress worsens both bladder and gastrointestinal symptoms, such as chronic pain felt by CBP patients ([@r6],[@r56]-[@r59]). The mechanisms that lead to colon-bladder cross-talk during chronic stress are mediated by an increase in plasma corticosterone levels ([@r60]). Curiously, the increase of corticosterone levels early in life leads to a chronic alteration of the sympathetic nervous system that result in increased levels of plasmatic noradrenaline ([@r61]), indicating a possible role of sympathetic overactivity in stress-induced CBP.

Spanos and co-workers have observed that chronic stress promotes the activation of bladder mast cells ([@r62]). The activation is induced by CAP sensitive fibres that sprout in the bladder wall near mast cells ([@r62]). Interestingly, Cikler and co-workers have observed that the increase in mast cells activation in the skin of rats subjected to the water avoidance stress model was prevented by the pre-treatment with melatonin ([@r63]), a molecule known to have a reverse effect in plasmatic noradrenaline levels. These results seem to indicate that there is a relation between CBP, mast cells activation, nociceptive fibres activation and sympathetic activity. Further corroborating this hypothesis, in another study using an animal model of chronic adrenergic stimulation, it was observed that PHE induced an increase in the number of mast cells present in the bladder mucosa, accompanied with CBP ([@r5]). The pre-treatment with CAP reversed the PHE induced CBP ([@r5]) and mast cell infiltration ([*Figure 3*](#f3){ref-type="fig"}).

![Graph bar showing mean values of number of mast cell infiltration per square millimetre of urinary bladder mucosa. Animals subcutaneously receiving 2.5 mg of PHE per kg of body weight (PHE 2.5 mg/kg, n=4), for 14 days, presented more mast cells than control animals (\*\*, P\<0.01, n=4). Pre-treatment with 75 mg CAP before the PHE treatment (PHE 2.5 mg/kg + CAP, n=4) reverse the PHE induced mast cell infiltration. PHE, phenylephrine; CAP, capsaicin; \*, P\<0.05.](tau-04-05-534-f3){#f3}

In some cases, stress may lead to urothelial degeneration (detachment and loss of urothelial cells, focal decrease in the urothelium cell layer and GAG layer irregularity), promoting dilated tight junctions ([@r64],[@r65]). Another study showed that this effect was reversed both by melatonin and CAP pre-treatment, indicating that they are downstream events to sympathetic and nociceptive fibre activation ([@r64],[@r65]). The chronic stress-induced mast cell activation and urothelial disruption can also be reverted by taurine ([@r66]). Taurine is known to suppress sympathetic nervous system activity ([@r67]), which further suggests the involvement of sympathetic nervous system in CBP induced by stress.

Sympathetic nervous system and other chronic pain disorders
===========================================================

CBP is often associated with other painful conditions such as IBS and fibromyalgia ([@r4]), which seems to be indicative of a common systemic etiology. There is ample support for an involvement of the sympathetic nervous system in triggering and maintaining of pain associated with these pathologies.

Heitkemper and co-workers interviewed and followed 24 female IBS patients and 25 healthy female aiming to describe and compare their levels of urinary catecholamines ([@r68]). Similar to what was observed to CBP patients, IBS patients also presented higher urine noradrenaline levels than controls ([@r68]). Burr and co-workers compared plasma catecholamine levels during sleep of 30 female patients with IBS with 31 healthy controls, and also observed that patients with IBS presented higher plasmatic noradrenaline levels than controls ([@r69]). Winston and co-workers have shown that noradrenaline induces visceral hypersensitivity upon colorectal distension induced by stress, through a nerve growth factor dependent mechanism ([@r70]). The increase in nerve growth factor levels may sensitizes primary afferents in the absence of an inflammatory response ([@r70]). In addition, Mazur and co-workers performed resting and functional autonomic nervous system tests and percutaneous electrogastrography in 30 patients with IBS and 30 healthy volunteers and observed that these patients presented increased sympathetic activation ([@r71]). These authors also collected blood samples to analyse plasmatic noradrenalin and also observed that IBS patients had substantially higher plasma catecholamine concentration, which further support a sympathetic nervous system dysfunction ([@r71]).

Fibromyalgia symptoms also suggest an impairment of sympathetic nervous system associated with chronic pain. In a study involving fibromyalgia patients and healthy individuals, Anderberg and co-workers analysed the levels of the sympathetic neurotransmitter neuropeptide Y in the plasma of those patients ([@r72]). These authors observed an increase in plasmatic neuropeptide Y levels compared to healthy subjects ([@r72]). Furthermore, in order to study a possible correlation between plasmatic neuropeptide Y levels changes and pain, the patients were followed for 28 days and 15 different symptoms were daily registered ([@r72]). Although there was a correlation between physical symptoms and plasmatic neuropeptide Y levels, the change in neuropeptide levels did not correlate with pain ([@r72]). Curiously, Yunus and collaborators have analysed plasmatic and urinary catecholamines in 30 patients with primary fibromyalgia and 30 healthy controls, without significant pain, and observed that there was no differences in between catecholamines levels in these groups ([@r73]). These results suggest that noradrenaline release by sympathetic fibres in fibromyalgia is secondary to fibromyalgia symptoms, without excluding its associated with pain arousal ([@r73]). Using 20 patients with fibromyalgia and 20 healthy controls, Martinez-Lavin and co-workers have injected noradrenaline in a forearm and saline solution in the opposite forearm of the studied subjects and registered maximum local pain elicited using a visual analogue scale ([@r74]). The norepinephrine-evoked pain was more frequent and intense in fibromyalgia patients than in healthy subjects ([@r74]). This observation further indicates that pain associated with fibromyalgia is driven by sympathetic nervous system ([@r74]). Recently, Zamunér and co-workers assessed whether there is a relationship between sympathetic activity and pain intensity. For that, cardiac activity and post-ganglionic sympathetic discharge activity were analysed in 25 patients with primary fibromyalgia ([@r75]). These authors observed a positive correlation between the sympathetic drive and the magnitude of chronic pain ([@r75]), further confirming the role of sympathetic overactivity in chronic pain arousal and maintenance.

The CBP-independent chronic regional pain syndrome also seems to present a correlation between chronic pain and a sympathetic dysfunction. This association is based on the observed vasomotor instability and a positive response to sympathetic blockade ([@r76]-[@r80]). Also, it has been described that intradermal injection of PHE or noradrenaline in complex regional pain syndrome patients induced abnormal pain response and mechano-allodynia around the injection site, contrary to the brief stinging pain observed in healthy individuals ([@r81]).

Conclusions
===========

Abnormalities in autonomic (sympathetic) activity have been demonstrated in CBP and this has been described both at a clinical and at an experimental level. Although several studies suggest a link between sympathetic overactivity and CBP, additional research is necessary to understand the underlying mechanisms. The confirmation of such hypothesis may help our understanding of how abnormalities in autonomic function may contribute to the pathophysiology of a number of chronic pelvic pain disorders.
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